133 STAT. 947  PUBLIC LAW 116–22—JUNE 24, 2019  (including additions, modifications, and replenish- ments) in the stockpile, and how such expenditures  relate to the ability of the stockpile to meet emergency  health security needs;  ‘‘(vii) an assessment of the extent to which addi- tions, modifications, and replenishments reviewed  under paragraph (2) align with previous relevant  reports or reviews by the Secretary or the Comptroller  General;  ‘‘(viii) with respect to any change in the Federal  organizational management of the stockpile, an assess- ment and comparison of the processes affected by such  change, including planning for potential counter- measure deployment, distribution, or dispensing  capabilities and processes related to procurement  decisions, use of stockpiled countermeasures, and use  of resources for such activities; and  ‘‘(ix) an assessment of whether the processes and  procedures described by the Secretary pursuant to sec- tion 403(b) of the Pandemic and All-Hazards Prepared- ness and Advancing Innovation Act of 2019 are suffi- cient to ensure countermeasures and products under  consideration for procurement pursuant to subsection  (a) receive the same consideration regardless of  whether such countermeasures and products receive  or had received funding under section 319L, including  with respect to whether such countermeasures and  products are most appropriate to meet the emergency  health security needs of the United States.  ‘‘(B) SUBMISSION.—Not later than 6 months after com- pleting a classified version of the review under subpara- graph (A), the Comptroller General shall submit an  unclassified version of the review to the congressional  committees of jurisdiction.’’.  Deadline.  (b) ADDITIONAL REPORTING.—In the first threat-based review  submitted after the date of enactment of this Act pursuant to  paragraph (2) of section 319F–2(a) of the Public Health Service  Act (42 U.S.C. 247d–6b(a)), as amended by subsection (a), the  Secretary shall include a description of the processes and procedures  through which the Director of the Strategic National Stockpile  and the Director of the Biomedical Advanced Research and Develop- ment Authority coordinate with respect to countermeasures and  products procured under such section 319F–2(a), including such  processes and procedures in place to ensure countermeasures and  products under consideration for procurement pursuant to such  section 319F–2(a) receive the same consideration regardless of  whether such countermeasures or products receive or had received  funding under section 319L of the Public Health Service Act (42  U.S.C. 247d–7e), and whether such countermeasures and products  are the most appropriate to meet the emergency health security  needs of the United States.  (c) AUTHORIZATION OF APPROPRIATIONS, STRATEGIC NATIONAL  STOCKPILE.—Section 319F–2(f)(1) (42 U.S.C. 247d–6b(f)(1)) is  amended by striking ‘‘$533,800,000 for each of fiscal years 2014  through 2018’’ and inserting ‘‘$610,000,000 for each of fiscal years  2019 through 2023, to remain available until expended’’. 